• Earlier in June 2026, Neurocrine Biosciences reported new data at ENDO 2026 showing CRENESSITY (crinecerfont) delivered strong hormonal control and glucocorticoid-sparing benefits in classic congenital adrenal hyperplasia, including the rarer 11ß-hydroxylase deficiency subtype.
• The combination of long-term Phase 3 outcomes and first-of-its-kind real-world evidence in this understudied CAH subgroup adds depth to CRENESSITY’s profile in rare endocrine care.
• Next, we’ll consider how this new evidence for improved cardiometabolic outcomes with CRENESSITY could shape Neurocrine Biosciences’ investment narrative.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

Neurocrine Biosciences Investment Narrative Recap

To own Neurocrine Biosciences today, you have to believe INGREZZA and CRENESSITY can keep driving growth while the company carefully manages pricing pressure and payer scrutiny. The latest ENDO 2026 data strengthen CRENESSITY’s profile in classic CAH, including the rarer 11ß-hydroxylase deficiency, but they do not materially change the near term focus on reimbursement durability and portfolio concentration risk around its two key franchises.

The most directly relevant update is the two year CAHtalyst Adult Phase 3 data, which link CRENESSITY use to improved cardiometabolic markers alongside lower glucocorticoid doses. In the context of analysts already viewing CRENESSITY as an important growth pillar, these outcomes add clinical depth that could influence payer and physician views, and may become part of how investors assess the balance between upside from broader CAH adoption and exposure to future pricing or access constraints.

Yet alongside this stronger CRENESSITY story, investors should be aware that concentrated dependence on just two products could become a problem if...

Neurocrine Biosciences' narrative projects $5.1 billion revenue and $1.5 billion earnings by 2029. This requires 18.0% yearly revenue growth and an earnings increase of about $831 million from $668.6 million today.

Uncover how Neurocrine Biosciences' forecasts yield a $192.88 fair value, a 22% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already cautious, assuming revenue of about US$4.7 billion and earnings near US$865.8 million by 2029, and they worry that heavier payer bargaining could chip away at CRENESSITY’s real world pricing power even as these new ENDO 2026 data emerge, so it is worth weighing their stricter view alongside the more optimistic expectations before deciding which long term story you believe.

Explore 3 other fair value estimates on Neurocrine Biosciences - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Neurocrine Biosciences research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Neurocrine Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neurocrine Biosciences' overall financial health at a glance.

Curious About Other Options?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.